Stenabolic (SR9009)

Why buy Stenabolic from us?

• HPLC-verified purity batch-specific certificate of analysis with every order
• UK warehouse same-day dispatch & next-day UK delivery
• Secure checkout all major cards accepted
• Discreet packaging as standard

What Is Stenabolic (SR9009)?

Stenabolic, scientifically known as SR9009, is a synthetic Rev-ErbA agonist developed by Professor Thomas Burris at Scripps Research Institute. It is often grouped with SARMs on supplement sites; however, SR9009 is not a selective androgen receptor modulator; it does not bind to androgen receptors and has no direct interaction with testosterone or other sex hormones.

In contrast, SR9009 targets nuclear receptors Rev-Erbα and Rev-Erbβ, which are key regulators of the circadian clock, energy metabolism, and lipid homeostasis. In preclinical studies, SR9009 altered the expression of metabolic genes in the liver, skeletal muscle, and adipose tissue, leading to increased energy expenditure and reduced fat mass in diet-induced obese mice.

SR9009 is strictly supplied as a research chemical. It is not approved for human use or consumption by the MHRA, FDA, EMA, or any other regulator worldwide.

How Does SR9009 Work?

SR9009 binds to and activates Rev-Erbα and Rev-Erbβ, respectively. These receptors act as transcriptional repressors of genes involved in:

• Glucose metabolism
• Lipid storage and oxidation
• Circadian rhythm regulation

In animal models, activation of Rev-Erbα by SR9009 has been observed to:

• Increase mitochondrial number and oxidative capacity in skeletal muscle
• Promote fat oxidation and reduce stored adipose tissue
• Enhance running endurance in previously untrained animals
• Improve markers of dyslipidaemia and hyperglycaemia

A 2013 study in Nature Medicine showed that Rev-Erbα activation with SR9009 increased metabolic activity in the skeletal muscle in both cell culture and live mice. Treated animals developed muscle gene expression patterns resembling those seen in exercise-trained subjects.

Key Research Areas

Preclinical research has explored SR9009 in several domains.

• Metabolism and circadian disruption: Chronic low-dose SR9009 has been shown to mitigates constant-light-induced weight gain, insulin resistance, and white fat accumulation in mice, primarily by inhibiting adipogenesis.
• Cardiac function: In mouse models of myocardial ischaemia-reperfusion, short-term SR9009 administration after the insult has been reported to reduce infarct expansion and prevent progression to heart failure by modulating the cardiac inflammasome.

All of these findings are preclinical, conducted in animal or in vitro models, not in humans.

Pharmacokinetics Half-Life & Bioavailability

Preclinical pharmacokinetic data indicate that SR9009 has a relatively short half-life of approximately 4 h in animal models. Therefore, research protocols often employ multiple daily administrations to maintain stable compound levels during experiments.

The oral bioavailability of this compound in mice is approximately 2-3%, with most of the administered dose undergoing first-pass metabolism in the liver before reaching systemic circulation. No human pharmacokinetic studies have been published; therefore, the fraction of an oral dose that reaches the bloodstream in humans remains unknown.

Legal Status & WADA Classification

In the United Kingdom, SR9009 is not classified as a controlled substance under the Misuse of Drugs Act of 1971 or the Psychoactive Substances Act of 2016. It can be legally purchased and possessed for research purposes.

However:

• SR9009 is not approved for use as a medicine, supplement, or food product.
• It must not be sold or marketed for human consumption.
• All products were supplied as laboratory research chemicals.

SR9009 is listed on the World Anti-Doping Agency (WADA) Prohibited List under S4 Hormone and Metabolic Modulators, specifically as a Rev-Erbα agonist (grouped with SR9011). It is prohibited at all times, in and out of competition, for athletes subject to WADA-governed anti-doping rules to use cannabis.

Frequently Asked Questions

Is Stenabolic a SARM?
No. Stenabolic (SR9009) is a Rev-ErbA agonist that does not interact with androgen receptors. It is sometimes marketed alongside SARMs because of similar research contexts, but its mechanism of action is completely different.

Has SR9009 been tested in humans?
No. No human clinical trials on SR9009 have been published. All existing data are derived from animal models and in vitro experiments. SR9009 is supplied solely for research purposes.

Does SR9009 suppress testosterone levels?
SR9009 is a non-hormonal compound that does not bind to androgen receptors. In preclinical studies, it has not been associated with the suppression of endogenous testosterone production.

What is the half-life of SR9009?
In animal pharmacokinetic studies, SR9009 has a half-life of approximately 4 h. Research protocols typically use divided dosing schedules (e.g. multiple daily administrations) to maintain exposure during experiments.

Why is oral bioavailability a concern?
Preclinical data in mice suggest that oral bioavailability is only approximately 2-3%, indicating that most of the compound is metabolised before reaching systemic circulation. As no human pharmacokinetic data are available, the effectiveness of oral administration in humans remains unclear.

Is Stenabolic banned in sports?
Yes. SR9009 is banned by WADA under S4 (Hormone and Metabolic Modulators) as a Rev-Erbα agonist and is prohibited at all times for athletes in WADA-compliant sports.

Is SR9009 legal to buy in the UK?
Yes, SR9009 is not a controlled drug and can be purchased for research. It cannot be legally sold as a supplement or medicine and is not approved for human consumption.

What forms of stenabolic do you stock?
We offer SR9009 in capsules, liquid solutions, and as raw powder. All formats were manufactured to ≥99% purity and verified by independent HPLC analysis, with a batch-specific certificate of analysis provided for each product.

What is the difference between SR9009 and SR9011?
Both SR9009 and SR9011 are synthetic Rev-ErbA agonists developed by the Scripps Research Institute. SR9011 is a follow-up compound with different structural features and limited published research. Both are listed on the WADA Prohibited List under the Rev-Erbα agonist category.

How quickly will my order arrive?
Orders placed before 1:00 PM (Mon-Fri) are dispatched on the same day from our UK warehouse. Standard UK shipping is next-day tracked delivery.

References

Solt LA, Wang Y, Banerjee S, et al. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature. 2012;485(7396):62–68. doi:10.1038/nature11030

Woldt E, Sebti Y, Solt LA, et al. Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nature Medicine. 2013;19(8):1039–1046. doi:10.1038/nm.3213

Yang MY, Lin HY, Chen YY, et al. Chronic low-dose REV-ERBs agonist SR9009 mitigates constant light-induced weight gain and insulin resistance via adipogenesis modulation. Biomedical Journal. 2025 Jan 10;48(3):100830. doi:10.1016/j.bj.2025.100830. PMCID: PMC12277734

Reitz CJ, Alibhai FJ, Khatua TN, et al. SR9009 administered for one day after myocardial ischemia-reperfusion prevents heart failure in mice by ing the cardiac inflammasome. Communications Biology. 2019. doi:10.1038/s42003-019-0595-z

World Anti-Doping Agency. International Standard — Prohibited List 2025/2026. S4 Hormone and Metabolic Modulators; S4.4 Rev-Erbα agonists (SR9009, SR9011). https://www.wada-ama.org/en/prohibited-list

Sarms.io. SR9009 Bioavailability: Oral Dosing vs Injections. https://sarms.io/sr9009-bioavailability/

​